Sonnet BioTherapeutics (SONN)
(Delayed Data from NSDQ)
$0.86 USD
-0.01 (-1.00%)
Updated Jul 25, 2024 10:11 AM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Sonnet BioTherapeutics Holdings, Inc falls in the month of September.
All items in Millions except Per Share data.
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 2 | 3 | 28 | 7 | 1 |
Receivables | 1 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 2 | 1 | 0 | 0 |
Total Current Assets | 5 | 5 | 29 | 8 | 1 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 6 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 12 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 5 | 6 | 29 | 8 | 32 |
Liabilities & Shareholders Equity | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 5 | 4 | 2 | 8 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 7 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3 | 3 | 2 | 2 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 1 | 1 | 2 |
Total Current Liabilities | 6 | 8 | 7 | 5 | 18 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 1 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 6 | 8 | 7 | 5 | 35 |
Shareholders Equity | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 110 | 89 | 84 | 40 | 72 |
Retained Earnings | -110 | -91 | -62 | -37 | -75 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 0 | -3 | 22 | 3 | -3 |
Total Liabilities & Shareholder's Equity | 5 | 6 | 29 | 8 | 32 |
Total Common Equity | 0 | -3 | 22 | 3 | -3 |
Shares Outstanding | 1.70 | 0.20 | 0.20 | 0.00 | 0.00 |
Book Value Per Share | -0.14 | -12.70 | 111.30 | 3.02 | -3.15 |
Fiscal Year End for Sonnet BioTherapeutics Holdings, Inc falls in the month of September.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 4 | 3 | 2 | 7 |
Receivables | NA | 0 | 0 | 1 | 1 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 1 | 1 | 2 | 2 |
Total Current Assets | NA | 5 | 5 | 5 | 10 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 6 | 5 | 5 | 10 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 2 | 2 | 3 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 1 | 1 | 3 | 3 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 3 | 3 | 6 | 6 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 3 | 3 | 6 | 7 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 114 | 114 | 110 | 110 |
Retained Earnings | NA | -111 | -111 | -110 | -107 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 3 | 3 | 0 | 3 |
Total Liabilities & Shareholder's Equity | NA | 6 | 5 | 5 | 10 |
Total Common Equity | 0 | 3 | 3 | 0 | 3 |
Shares Outstanding | 3.10 | 3.10 | 3.00 | 1.70 | 1.70 |
Book Value Per Share | 0.00 | 0.98 | 0.86 | -0.14 | 2.01 |